PHARMACOKINETIC INTERACTION OF ZONISAMIDE IN RATS - EFFECT OF OTHER ANTIEPILEPTICS ON ZONISAMIDE

被引:18
作者
KIMURA, M
TANAKA, N
KIMURA, Y
MIYAKE, K
KITAURA, T
FUKUCHI, H
机构
[1] Department of Pharmaceutical Services, Hiroshima University Hospital, Minami-ku, Hiroshima 734, Kasumi
来源
JOURNAL OF PHARMACOBIO-DYNAMICS | 1992年 / 15卷 / 11期
关键词
ZONISAMIDE; PHARMACOKINETIC INTERACTION; ANTIEPILEPTIC DRUG; PROTEIN BINDING; ERYTHROCYTE DISTRIBUTION; METABOLISM;
D O I
10.1248/bpb1978.15.631
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics Of zonisamide (ZNS) and the effects of phenobarbital (PB), valproic acid (VPA), carbamazepine (CBZ) and phenytoin (PHT) on ZNS kinetics were investigated in rats. The effects of other antiepileptics on the serum protein binding, erythrocyte distribution and metabolism of ZNS were also studied in vitro to elucidate the mechanism of pharmacokinetic interaction of ZNS. ZNS showed a linear disposition kinetics after oral administration of ZNS within the dose examined. Moreover, the pharmacokinetic behaviors of ZNS were not altered after multiple dosing. The decreased t1/2 value of ZNS by PB or CBZ pretreatment and the increased Vd/F value of ZNS by VPA pretreatment were observed, although it showed no marked effect of PHT on ZNS kinetics. The enhanced metabolism of ZNS was observed by PB or CBZ pretreatmtent from an in vitro metabolism study. The serum protein binding and erythrocyte distribution of ZNS showed no significant change in the presence of other antiepileptics in vitro. These results indicate that the decreased t1/2 value of ZNS is attributable to the enzyme inducing effect of PB or CBZ, and that neither protein binding nor erythrocyte distribution of ZNS could be the reason for the increased Vd/F value of ZNS by VPA coadministration.
引用
收藏
页码:631 / 639
页数:9
相关论文
共 27 条
[1]  
ANTON AH, 1961, J PHARMACOL EXP THER, V134, P291
[2]  
CUCINELL SA, 1972, ANTIEPILEPTIC DRUGS, P319
[3]   VALPROIC ACID PHENYTOIN INTERACTION [J].
FRIEL, PN ;
LEAL, KW ;
WILENSKY, AJ .
THERAPEUTIC DRUG MONITORING, 1979, 1 (02) :243-248
[4]  
HANSEN JM, 1971, CLIN PHARMACOL THER, V12, P539
[5]   ERYTHROCYTE CARRIERS [J].
IHLER, GM .
PHARMACOLOGY & THERAPEUTICS, 1983, 20 (02) :151-169
[6]   MECHANISM OF VALPROATE-PHENOBARBITAL INTERACTION IN EPILEPTIC PATIENTS [J].
KAPETANOVIC, IM ;
KUPFERBERG, HJ ;
PORTER, RJ ;
THEODORE, W ;
SCHULMAN, E ;
PENRY, JK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (04) :480-486
[7]  
KIMURA M, 1992, CHEM PHARM BULL, V40, P193
[8]  
KOHDA Y, 1983, J PHARMACOBIO-DYNAM, V6, P46
[9]  
KONISHI H, 1990, Yakuzaigaku, V50, P323
[10]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265